Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.

Authors
  • Duchnowska, Renata
  • Sperinde, Jeff
  • Chenna, Ahmed
  • Haddad, Mojgan
  • Paquet, Agnes
  • Lie, Yolanda
  • Weidler, Jodi M
  • Huang, Weidong
  • Winslow, John
  • Jankowski, Tomasz
  • Czartoryska-Arłukowicz, Bogumiła
  • Wysocki, Piotr J
  • Foszczyńska-Kłoda, Małgorzata
  • Radecka, Barbara
  • Litwiniuk, Maria M
  • Zok, Jolanta
  • Wiśniewski, Michał
  • Zuziak, Dorota
  • Biernat, Wojciech
  • Jassem, Jacek
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
May 15, 2014
Volume
20
Issue
10
Pages
2805–2813
Identifiers
DOI: 10.1158/1078-0432.CCR-13-2782
PMID: 24668646
Source
Medline
License
Unknown

Abstract

The consistency in the p95 VeraTag cutoff across different cohorts of patients with MBC treated with trastuzumab justifies additional studies using blinded analyses in larger series of patients.

Report this publication

Statistics

Seen <100 times